SRPT Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 33.55%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Amgen, Inc.'s return on equity of 95.55%.

Sarepta Therapeutics, Inc. has a consensus price target of $20.70, signalling downside risk potential of -13.15%. On the other hand Amgen, Inc. has an analysts' consensus of $330.41 which suggests that it could grow by 1.32%. Given that Amgen, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Amgen, Inc. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.485, which suggesting that the stock is 51.536% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.454, suggesting its less volatile than the S&P 500 by 54.551%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.92% to investors and pays a quarterly dividend of $2.38 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Amgen, Inc.'s PE ratio is 25.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 1.02x versus 4.92x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Arrowhead Pharmaceuticals, Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 6.29%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.

Sarepta Therapeutics, Inc. has a consensus price target of $20.70, signalling downside risk potential of -13.15%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $77.91 which suggests that it could grow by 20.68%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.485, which suggesting that the stock is 51.536% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, suggesting its more volatile than the S&P 500 by 20.893%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are larger than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 1.02x versus 10.39x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 17.96%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Sarepta Therapeutics, Inc. has a consensus price target of $20.70, signalling downside risk potential of -13.15%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $56.26 which suggests that it could grow by 0.72%. Given that Bristol Myers Squibb Co. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Bristol Myers Squibb Co. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.485, which suggesting that the stock is 51.536% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.215%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.46% to investors and pays a quarterly dividend of $0.63 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Bristol Myers Squibb Co.'s PE ratio is 18.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 1.02x versus 2.37x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -45.06% compared to Sarepta Therapeutics, Inc.'s net margin of 21.32%. Sarepta Therapeutics, Inc.'s return on equity of -20.67% beat Pfizer Inc.'s return on equity of 10.84%.

Sarepta Therapeutics, Inc. has a consensus price target of $20.70, signalling downside risk potential of -13.15%. On the other hand Pfizer Inc. has an analysts' consensus of $28.66 which suggests that it could grow by 12.47%. Given that Pfizer Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Sarepta Therapeutics, Inc..

Sarepta Therapeutics, Inc. has a beta of 0.485, which suggesting that the stock is 51.536% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Sarepta Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.75% to investors and pays a quarterly dividend of $0.43 per share. Sarepta Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Sarepta Therapeutics, Inc. quarterly revenues are $399.4M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Sarepta Therapeutics, Inc.'s net income of -$179.9M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Sarepta Therapeutics, Inc.'s price-to-earnings ratio is 20.50x while Pfizer Inc.'s PE ratio is 14.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics, Inc. is 1.02x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.